Abivax SA - American Depositary Shares (ABVX) is currently showing a slightly bearish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently weak earnings tone.
HEADLINE TAKE: There is a mild negative lean in the higher-value headlines, though the setup is not strong enough to call decisively bearish.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
39/100
Slightly Bearish
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$136.26
Trend Context
Mixed / range
Latest briefing
What's happening with ABVX
seekingalpha.com16 Jul 2026
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Abivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obefazimod in ulcerative colitis. ABVX demonstrated clinical remission rates of 50.8%–51.3% at week 44, with strong secondary endpoints and a favorable safety profile. A recent $920M capital raise funds operations into Q4 2029, enabling standalone commercialization and strengthening strategic positioning.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
cnbc.com10 Jul 2026
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under intense scrutiny as an acquisition target by a larger peer.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
fool.com7 Jul 2026
3 Soaring Stocks That May Have More Upside Ahead
The sky is the limit for these companies.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
6 Jul 2026
Abivax Announces Closing of $920 Million Public Offering
